Trimesta will be partnered, will need raises (about $150M) for the other two P3 programs for 2016.
Depending on share price, the dilution could be moderate to somewhat substantial in 2016. It all depends on the share price at the time of dilution.
Agreed. It's just it's taking them sooo, sooo long to players in the CAR-T space.
Anyway, is there a ONCS presentation this coming week? If so, when/where? TIA.
Come back and talk to us next week when it's in the 5s.
You've obviously lost a lot of money by following Zack's advice.
Come back an talk to us next week when it's under $4.
Ready to eat crow?
Among other positions, I've actually been trading in and out of ADXS and ATHX. Both are great companies and stocks to hold.
At this time, I do not hold a position in ADXS but do have a position in ATHX. I could be wrong, but I expect ADXS to briefly "cool" its jets while I expect ATHX to break much higher once we get past 3.00.
The bottom line is that there are very few "bad" biotechs these days. Easy money to be made everywhere. Pick your elixir and good luck!
Thanks for all of the info... much appreciated.
So, would it be too much to assume that the run-up could begin someday next week and ultimately bring us north of $3.50 before data?
So, given this new partnership, how does everyone believe a run-up to data will occur?
We seem to have built support around 2.90. When will the run-up from here begin and does the partnership place a new level on the magnitude of a potential run-up to data?
See full article with links at: http://biojaxusa.blogspot.com/
How much are Athersys shares worth ahead of the data release? It's certainly believed to be higher than the current trade area by many. Will 2015 be a repeat of 2014, the question on may investors minds? The science seems to support the opposite. Edison Investment Research has some valuation comments here: Athersys - Poised for pivotal stroke data. Obviously plugging in the formula Edison's using - a successful showing for MultiStem in the coming data release would value the stock at about $15.40 per share.
If the Edison price targets mentioned above seem high to investors - think again! Osiris shares reached a per share price of $27.40 on August 14, 2013 related to news surrounding its then adult stem cell program using an apparently inferior cell. Investors should also look at Alnylam, Pharmaceuticals, Inc. (NASDAQ: ALNY) and read here: Athersys, Inc.The Next Alnylam Pharmaceuticals, Inc. The fact is Alnylam an RNAi technology company has a great deal of interest in stem cells for a reason. To date Alnylam has marketed nothing!